Heidelberg Pharma (HPHA.DE) stock: key figures, P/E, revenue and dividend
Health Care · Germany · ISIN DE000A11QVV0
Heidelberg Pharma financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 6.85 m EUR | 1.46 m EUR |
| Gross profit | 5.00 m EUR | -1.00 m EUR |
| Operating income | -21.83 m EUR | -48.93 m EUR |
| EBIT | -20.00 m EUR | -47.00 m EUR |
| Net income | -19.00 m EUR | -42.00 m EUR |
| Diluted EPS – continuing operations | -0.42 EUR | -0.90 EUR |
Full history since 2006, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Heidelberg Pharma
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally. The company's lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It also develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma; HDP-103, a proprietary ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors; HDP-201 for the treatment of colorectal cancer; and TAK-ATAC for the treatment of oncology. In addition, the company develops TLX250-CDx, a diagnostic antibody for kidney cancer that is in Phase III trials, as well as for the treatment of bladder cancer. Further, it develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for the treatment of kidney cancer; and RHB-107, an orally serine protease inhibitor that is in Phase II study to treat COVID-19. The company has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia, and Antibody Drug Conjugates (ADCs). The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is headquartered in Ladenburg, Germany.
More stocks
- BNCCorp Inc (BNCC)
- Jati Tinggi Group Berhad (0292.KL)
- Info-Tek (8183.TWO)
- Indonesia Fibreboard Industry PT (IFII.JK)
- Silla Co.Ltd (004970.KS)
- FLANIGANS ENTERPRISES INC (BDL)
- Shanghai Jinjiang International Travel Co Ltd (900929.SS)
- IMMUNIC, INC. (IMUX)
- GoPro, Inc. (GPRO)
- Hsin Ba Ba Corp (9906.TW)
- Canagold Resources Ltd (CCM.TO)
- RAC Electric Vehicles Inc. (2237.TWO)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.